my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
18-05-2012: Lab21 Limited has secured new patents in Europe and the USA relating to Hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.
The patents cover technology allowing the genotypic identification of drug resistant mutations in the four major global genotypes of HCV. The new patents represent successful extensions of the original European approval, granted in 2009. The US patent is the first successful patent Lab21 has secured in North America to protect its growing business.
Dr Berwyn Clarke, CSO at Lab21 commented: ‘Lab21 has extensive experience in the area of antiretroviral drug resistance from many years of working in HIV. With the number of new HCV therapeutics in development and the changeable nature of the virus, we expect routine resistance analysis for HCV patients to be introduced into clinical guidelines in the near future. Our IP in this area will be of great importance to the clinical management of these patients and will enable easy drug resistance monitoring during clinical trials.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Lab21 announces sale of South Carolina Operations
Lab21 Limited announced the sale of its laboratory operations based in South Carolina to Reedy Acquisitions Corp, an entity formed by the existing local management and South Carolina based investors. In addition to an immediate cash benefit for Lab21 Ltd, the sale will remove a loss-making ... more
Lab21 secures European and USA patents for HCV drug resistance genotyping
Lab21 Limited has secured new patents in Europe and the USA relating to Hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing. The patents cover technology allowing the genotypic identification of drug resistant mutat ... more
Lab21 launches new lung cancer companion diagnostic service
Lab21 Limited has launched a new Companion Diagnostic testing service for non-small cell lung cancer patients.The EML4-ALK companion diagnostic test for translocations in the ALK gene will allow physicians to select lung cancer patients likely to respond to ALK inhibitor therapy. The test u ... more
Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting drug discovery, healthcare and environmental monitoring. Its customers include healthcare providers, pharmaceutical and biotechnology companies, in addition to organisations that need to monitor thei ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
